ArticleInternational journal of general medicine2025
Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: aFrontiers in immunology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plaque psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease. This study aimed to investigate effectiveness of interleukin (IL)-17A inhibitor treatment and effectiveness after treatment interruption in plaque psoriasis patients and analyze the related factors. Methods: This study retrospectively collected clinical characteristics and related treatment status of plaque psoriasis patients treated with IL-17A inhibitors, and evaluated the treatment effectiveness, reasons for treatment interruption, effectiveness after treatment interruption, and risk factors affecting treatment effectiveness. Results: This study ultimately included 106 patients with plaque psoriasis, including 61 males (57.55%) and 45 females (42.45%), aged 41.0 (31.0-54.0) years and with a disease duration of 12.0 (8.0-20.0) months. Among them, 71 cases (67%) achieved PASI90 after receiving IL-17A inhibitor treatment, and 35 cases (33.02%) achieved PASI75. A total of 50 patients (50/106, 47.17%) interrupted treatment, 23 patients (23/50, 46%) maintained a therapeutic effect of PASI90 or above, and 27 patients (27/50, 54%) had a therapeutic effect lower than PASI75, with median time of treatment interruption of 1.0 (1.0-3.5) months. Univariate analysis findings showed that duration of IL-17A inhibitor treatment interruption and reasons for interruption had significant statistical significance on treatment effectiveness (all P<0.05). In multivariate analysis, treatment interruption (OR=7.154, 95% CI: 2.528-20.24) and reasons such as stress/anxiety (OR: 14.889, 95% CI: 1.160-23.480) were risk factors affecting treatment effectiveness. Conclusion: Interleukin (IL)-17A inhibitor treatment interruption plays critical effects on the treatment of plaque psoriasis. Early and long-term adherence to IL-17A inhibitor treatment can control the course of the disease and improve the long-term health of psoriasis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.